| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sangamo Biosciences Inc. > News item |
Sangamo licenses MaxCyte cell loading technology for HIV/AIDS program
By E. Janene Geiss
Philadelphia, March 2 - MaxCyte, Inc. and Sangamo BioSciences, Inc. announced Thursday a license, option, development and supply agreement to use MaxCyte's proprietary cell loading system for use in Sangamo's HIV/CCR5 ZFP Therapeutic program.
The two companies have begun a research and development plan to evaluate and further develop the GMP-compliant MaxCyte system to load zinc finger DNA-binding protein (ZFP)-based therapeutics into cells. Sangamo also has the option to use MaxCyte's system for ZFP Therapeutics in oncology, according to a joint news release.
The agreement provides Sangamo an option for a commercial license to MaxCyte's technology that includes a supply contract and clinical and commercial milestones to MaxCyte for products developed under the agreement.
Under the license, Sangamo said it has the right to reference MaxCyte's FDA Master File in its regulatory submissions.
Financial terms of the agreement were not disclosed.
"We believe MaxCyte's cell loading technology can be an important component of an ex vivo delivery system for our HIV T-cell program that uses ZFP nucleases (ZFN) to modify the gene for the CCR5 protein. A key part of our business model is to identify partners such as MaxCyte that have complementary delivery methods that can accelerate the clinical success of our programs and support their ultimate commercialization," Edward Lanphier, president and chief executive officer of Sangamo, said in the release.
MaxCyte is a Gaithersburg, Md., clinical-stage cell therapeutics company with a growing pipeline of partnered and internally developed therapeutic candidates.
Sangamo is a Richmond, Calif., biopharmaceutical company focused on development of novel DNA-binding proteins for therapeutic gene regulation and modification.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.